KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Capital Expenditures (2018 - 2025)

Vir Biotechnology's Capital Expenditures history spans 8 years, with the latest figure at $348000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 82.56% year-over-year to $348000.0; the TTM value through Dec 2025 reached $4.8 million, down 33.82%, while the annual FY2025 figure was $4.8 million, 33.82% down from the prior year.
  • Capital Expenditures for Q4 2025 was $348000.0 at Vir Biotechnology, up from $317000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $20.6 million in Q2 2022 and bottomed at $317000.0 in Q3 2025.
  • The 5-year median for Capital Expenditures is $2.5 million (2021), against an average of $6.2 million.
  • The largest annual shift saw Capital Expenditures soared 4090.74% in 2022 before it tumbled 92.96% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $17.6 million in 2021, then decreased by 28.66% to $12.6 million in 2022, then plummeted by 87.79% to $1.5 million in 2023, then grew by 29.97% to $2.0 million in 2024, then tumbled by 82.56% to $348000.0 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Capital Expenditures are $348000.0 (Q4 2025), $317000.0 (Q3 2025), and $2.5 million (Q2 2025).